RT Journal Article SR Electronic T1 Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.10.18.21265113 DO 10.1101/2021.10.18.21265113 A1 Ai-ris Y. Collier A1 Catherine M. Brown A1 Katherine Mcmahan A1 Jingyou Yu A1 Jinyan Liu A1 Catherine Jacob-Dolan A1 Abishek Chandrashekar A1 Dylan Tierney A1 Jessica L. Ansel A1 Marjorie Rowe A1 Daniel Sellers A1 Kunza Ahmad A1 Ricardo Aguayo A1 Tochi Anioke A1 Sarah Gardner A1 Mazuba Siamatu A1 Lorraine Bermudez Rivera A1 Michele R. Hacker A1 Lawrence C. Madoff A1 Dan H. Barouch YR 2021 UL http://medrxiv.org/content/early/2021/10/20/2021.10.18.21265113.abstract AB Background A cluster of over a thousand infections with the SARS-CoV-2 delta variant was identified in a predominantly fully vaccinated population in Provincetown, Massachusetts in July 2021. Immune responses in breakthrough infections with the SARS-CoV-2 delta variant remain to be defined.Methods Humoral and cellular immune responses were assessed in 35 vaccinated individuals who were tested for SARS-CoV-2 in the Massachusetts Department of Public Health outbreak investigation.Results Vaccinated individuals who tested positive for SARS-CoV-2 demonstrated substantially higher antibody responses than vaccinated individuals who tested negative for SARS-CoV-2, including 28-fold higher binding antibody titers and 34-fold higher neutralizing antibody titers against the SARS-CoV-2 delta variant. Vaccinated individuals who tested positive also showed 4.4-fold higher Spike-specific CD8+ T cell responses against the SARS-CoV-2 delta variant than vaccinated individuals who tested negative.Conclusions Fully vaccinated individuals developed robust anamnestic antibody and T cell responses following infection with the SARS-CoV-2 delta variant. These data suggest important immunologic benefits of vaccination in the context of breakthrough infections.Competing Interest StatementDHB is a co-inventor on provisional vaccine patents (63/121,482; 63/133,969; 63/135,182). The authors report no other conflict of interest.Funding StatementThe authors acknowledge NIH grant CA260476, the Ragon Institute of MGH, MIT, and Harvard, the Massachusetts Consortium for Pathogen Readiness, and the Musk Foundation (D.H.B.). The authors also acknowledge the Reproductive Scientist Development Program from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and Burroughs Wellcome Fund HD000849 (A.Y.C.)x.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB) of Beth Israel Deaconess Medical Center (BIDMC) gave ethical approval for this work (#2021P000344)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript or the supplementary material.